This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novozymes, Chr. Hansen Complete Merger Settlement MT
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Nordic All-Share Index CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials (Industry Group) CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P International 700 CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global 1200 CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global BMI Index CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index CI
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S. CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals MT
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss DJ
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod MT
Novozymes-Chr. Hansen Merger Gets EU Nod After Proposed Asset Sale MT
Kerry Group Buys Novozymes, Chr. Hansen Assets for EUR150 Million DJ
European Commission clears Novozymes, Chr. Hansen merger RE
Kerry Group plc agreed to acquire Lactase enzyme business from Chr. Hansen Holding A/S and Novozymes A/S (CPSE:NZYM B) for ?150 million. CI
Simon Barnard: A long-term vision at Smithson Our Logo
EU regulators likely to clear Novozymes, Chr. Hansen deal, sources say RE
EU ANTITRUST REGULATORS LIKELY TO APPROVE NOVOZYMES, C… RE
EU Competition Watchdog Extends Novozymes, Chr. Hansen Merger Decision MT
EU extends decision date on Novoyzmes, Chr. Hansen deal to Dec. 12 RE
Novozymes, Chr. Hansen Propose Remedy to Secure EU Approval for Merger MT
Chart Christian Hansen
More charts
Chr. Hansen Holding A/S specializes in the development, production and marketing of biotechnological ingredients for the food processing, animal feed and health industries. Net sales (excluding activities being sold) break down by family of products as follows: - cultivations and enzymes (62.6%); - medical and nutritional ingredients (37.4%): used in the manufacturing of dietary supplements, OTC drugs, baby products and animal feed. Net sales are distributed geographically as follows: Denmark (0.8%), Europe/Middle East/Africa (36.4%), the United States (30.3%), North America (2.4%), Asia/Pacific (18.7%) and Latin America (11.4%).
More about the company
  1. Stock Market
  2. Equities
  3. CHR Stock
  4. News Christian Hansen
  5. Denmark's Novozymes, Chr. Hansen Enter Merger Deal to Create New Biosolutions Group